Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors.

Pezzicoli, Gaetano; Filoni, Elisabetta; Gernone, Angela; Cosmai, Laura; Rizzo, Mimma; Porta, Camillo

Pezzicoli, Gaetano; Filoni, Elisabetta; Gernone, Angela; Cosmai, Laura; Rizzo, Mimma; Porta, Camillo.

Afiliação

Pezzicoli G; Department of Biomedical Sciences and Human Oncology, Post-Graduate School of Specialization in Medical Oncology, University of Bari 'A. Moro', Bari, Italy.
Filoni E; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
Gernone A; Department of Biomedical Sciences and Human Oncology, Post-Graduate School of Specialization in Medical Oncology, University of Bari 'A. Moro', Bari, Italy.
Cosmai L; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
Rizzo M; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
Porta C; Onconephrology Outpatient Clinic, Division of Nephrology and Dialysis, A.S.S.T. Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, Italy.

Cancer Manag Res ; 13: 7623-7636, 2021.

Article em En | MEDLINE | ID: mdl-34675658

Palavras-chave

Rapa-Link; anti-angiogenics; autophagy; everolimus; temsirolimus

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Manag Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google